Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

Research output: Contribution to journal › Editorial › Research › peer-review

Standard

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? / Holst, Jens Juul.

In: The Lancet, Vol. 394, No. 10192, 2019, p. 4-6.

Research output: Contribution to journal › Editorial › Research › peer-review

Harvard

Holst, JJ 2019, 'Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?', The Lancet, vol. 394, no. 10192, pp. 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9

APA

Holst, J. J. (2019). Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet, 394(10192), 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9

Vancouver

Holst JJ. Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet. 2019;394(10192):4-6. https://doi.org/10.1016/S0140-6736(19)31350-9

Author

Holst, Jens Juul. / Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?. In: The Lancet. 2019 ; Vol. 394, No. 10192. pp. 4-6.

Bibtex

@article{7a05639db93249f5ba8627597a941d90,
title = "Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?",
author = "Holst, {Jens Juul}",
year = "2019",
doi = "10.1016/S0140-6736(19)31350-9",
language = "English",
volume = "394",
pages = "4--6",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10192",

}

RIS

TY - JOUR

T1 - Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

AU - Holst, Jens Juul

PY - 2019

Y1 - 2019

U2 - 10.1016/S0140-6736(19)31350-9

DO - 10.1016/S0140-6736(19)31350-9

M3 - Editorial

VL - 394

SP - 4

EP - 6

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10192

ER -

ID: 225957791